Top Markets
#1 Threshold Network Threshold Network +63.57%
#2 TENDIES TENDIES +56.27%
#3 Cash Cat Cash Cat +19.11%
#4 OSK OSK +15.52%
#5 Ape and Pepe Ape and Pepe +12.62%
#6 Magma Finance Magma Finance +11.91%
#7 龙虾 (Lobster) 龙虾 (Lobster) +11.33%
#8 Falcon Finance Falcon Finance +11.16%
#9 Safe Safe +9.82%
#10 Asteroid Shiba Asteroid Shiba +9.40%
Coin of the day
Threshold Network Threshold Network
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Cellectis S.A. Cellectis S.A.

Cellectis S.A.

ALCLS
Classement en actions #17130
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Prix de l'action
$3.56
Capitalisation boursière
$257.37M
Changement (1 jour)
5.26%
Changement (1 an)
38.35%
Pays
FR
Échange Cellectis S.A. (ALCLS)

Catégorie

Healthcare
Le prix ALCLS avec la capitalisation boursière de B
Cellectis S.A. Cellectis S.A.
ALCLS
$3.56
Capitalisation boursière de Cellectis S.A.(ALCLS)
Capitalisation boursière: $257.37M
En September 2026, Cellectis S.A. a une capitalisation boursière de $257.37M. Cela fait de Cellectis S.A. la 17130th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Cellectis S.A. du 2007 au 2026
ALCLS par rapport au top 5 des plus populaires stocks
Prix pour ALCLS L’actif B La capitalisation boursière de B Résultats
Cellectis S.A. Cellectis S.A.
$72,721.37 $257.37M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.260T +2,043,516.04%
Cellectis S.A. Cellectis S.A.
$66,069.80 $257.37M
Apple Inc. Apple Inc.
AAPL
$4.779T +1,856,593.57%
Cellectis S.A. Cellectis S.A.
$55,537.00 $257.37M
Alphabet Inc. Alphabet Inc.
GOOG
$4.017T +1,560,600.69%
Cellectis S.A. Cellectis S.A.
$51,424.59 $257.37M
Microsoft Corporation Microsoft Corporation
MSFT
$3.719T +1,445,033.97%
Cellectis S.A. Cellectis S.A.
$37,804.64 $257.37M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.734T +1,062,286.09%